Mural Oncology plc: restructuring charge — Mural Oncology ends nemvaleukin alfa development, cuts 90% of staff

Mural Oncology plc

Discontinues all clinical development of nemvaleukin alfa after phase 2 ARTISTRY-6 and phase 3 ARTISTRY-7 trial data.
Workforce reduction of approximately 104 positions, or about 90%, expected to complete by end of Q2 2025.
Estimated costs of $9.0-$10.0 million in severance and benefits, plus $2.0-$4.0 million in non-cash impairment charges.
Engages Lucid Capital Markets to explore strategic alternatives focused on maximizing shareholder value.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Mural Oncology plc announced a restructuring with charges of approximately $9.0 million to $10.0 million (approximately 104 positions, or approximately 90%).

Type: restructuring
Charge: approximately $9.0 million to $10.0 million
Headcount: approximately 104 positions, or approximately 90%

Exact text from the filing

90% (the “Reduction”). The Company expects to substantially complete the Reduction by the end of the second quarter of 2025. The Company expects to incur costs of approximately $9.0 million to $10.0 million related to the Reduction, primarily consisting of severance payments and employee benefit costs. Additionally, the Company expects to incur $2.0 million to $4.0

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Mural Oncology plc announced a impairment with charges of $2.0 million to $4.0 million affecting property and equipment.

Type: impairment
Charge: $2.0 million to $4.0 million
Affected area: property and equipment

Exact text from the filing

Additionally, the Company expects to incur $2.0 million to $4.0 million in non-cash impairment charges associated with property and equipment expected to be sold or otherwise disposed of.

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001193125-25-080765

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.